Attribution of human papillomavirus types to cervical intraepithelial neoplasia and invasive cancers in Southern China

International Journal of Cancer

Volumn 131, Issue 3, 2012, Pages 692-705

  Chan, Paul K S ^a   Cheung, Tak Hong ^a   Li, Wai Hon ^b   Yu, Mei Y ^a   Chan, May Y M ^b   Yim, So Fan ^a   Ho, Wendy C S ^a   Yeung, Apple C M ^a   Ho, King Man ^c   Ng, H K ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b QUEEN ELIZABETH HOSPITAL   (Hong Kong)

^c DEPARTMENT OF HEALTH   (Hong Kong)

Author keywords

Chinese; Hong Kong; prevalence; type replacement; vaccine

Indexed keywords

WART VIRUS VACCINE;

ADENOCARCINOMA; ARTICLE; CANCER GRADING; CANCER INVASION; CHINESE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HONG KONG; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 24; HUMAN PAPILLOMAVIRUS TYPE 26; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 33; HUMAN PAPILLOMAVIRUS TYPE 34; HUMAN PAPILLOMAVIRUS TYPE 35; HUMAN PAPILLOMAVIRUS TYPE 39; HUMAN PAPILLOMAVIRUS TYPE 40; HUMAN PAPILLOMAVIRUS TYPE 42; HUMAN PAPILLOMAVIRUS TYPE 44; HUMAN PAPILLOMAVIRUS TYPE 45; HUMAN PAPILLOMAVIRUS TYPE 51; HUMAN PAPILLOMAVIRUS TYPE 52; HUMAN PAPILLOMAVIRUS TYPE 53; HUMAN PAPILLOMAVIRUS TYPE 54; HUMAN PAPILLOMAVIRUS TYPE 56; HUMAN PAPILLOMAVIRUS TYPE 58; HUMAN PAPILLOMAVIRUS TYPE 6; MAJOR CLINICAL STUDY; NONHUMAN; PAPILLOMAVIRUS INFECTION; PREVALENCE; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; VIRUS DETECTION; WART VIRUS;

ALPHAPAPILLOMAVIRUS; CERVICAL INTRAEPITHELIAL NEOPLASIA; CHINA; FEMALE; HUMANS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; UTERINE CERVICAL NEOPLASMS;

EID: 84857411898     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.26404     Document Type: Article

References (32)

1. Arbyn M, Castellsagué X, de Sanjosé S, Bruni L, Saraiya M, Bray F, Ferlay J,. Worldwide burden of cervical cancer in 2008. Ann Oncol [Epub ahead of print April 6, 2011 ].
2. zur Hausen H,. Papillomavirus and cancer: from basic studies to clinical application. Nat Rev Cancer 2002; 2: 342-50.
3. Muñoz N,. Human papillomavirus and cancer: the epidemiological evidence. J Clin Virol 2000; 19: 1-5.
4. Franco EL, Rohan TE, Villa LL,. Epidemiologic evidence and human papillomavirus infection as a necessary cause of cervical cancer. J Natl Cancer Inst 1999; 91: 506-11.
5. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Muñoz N,. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189: 12-9.
6. Muñoz N, Bosch FX, de Sanjosé S, Herrero R, Castellsagué X, Shah KV, Snijders PJ, Meijer CJ,; International Agency for Research on Cancer Multicenter Cervical Cancer Study Group. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003; 348: 518-27.
7. Cogliano V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F,; WHO International Agency for Research on Cancer. Carcinogenicity of human papillomaviruses. Lancet Oncol 2005; 6: 204.
8. International Agency for Research on Cancer (IARC) working group. Human papillomaviruses. In: IARC monographs on the evaluation of carcinogenic risks to humans. vol. 90. Lyon: IARC Press, 2007. 1-670.
9. Harper DM, Franco EL, Wheeler CM, Moscicki AB, Romanowski B, Roteli-Martins CM, Jenkins D, Schuind A, Costa Clemens SA, Dubin G,; HPV Vaccine Study group. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 2006; 367: 1247-55.
10. Paavonen J, Naud P, Salmerõn J, Wheeler CM, Chow SN, Apter D, Kitchener H, Castellsague X, Teixeira JC, Skinner SR, Hedrick J, Jaisamrarn U, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009; 374: 301-14.
11. FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007; 356: 1915-27.
12. Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S, Tang GW, Ferris DG, Steben M, Bryan J, Taddeo FJ, Railkar R, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007; 356: 1928-43.
13. Smith JS, Lindsay L, Hoots B, Keys J, Franceschi S, Winer R, Clifford GM,. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer 2007; 121: 621-32.
14. Clifford GM, Smith JS, Plummer M, Muñoz N, Franceschi S,. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer 2003; 88: 63-73.
15. Clifford GM, Smith JS, Aguado T, Franceschi S,. Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis. Br J Cancer 2003; 89: 101-5.
16. Clifford GM, Rana RK, Franceschi S, Smith JS, Gough G, Pimenta JM,. Human papillomavirus genotype distribution in low-grade cervical lesions: comparison by geographic region and with cervical cancer. Cancer Epidemiol Biomarkers Prev 2005; 14: 1157-64.
17. Hong Kong Cancer Registry. Hospital Authority. Fast facts on cervical cancer 2008. Available at: http://www3.ha.org.hk/cancereg/e-cx.pdf. Retrieved 24 January 2008.
18. Chan PK, Ho WC, Wong MC, Chang AR, Chor JS, Yu MY,. Epidemiologic risk profile of infection with different groups of human papillomaviruses. J Med Virol 2009; 81: 1635-44.
19. Chan PK, Chan DP, To KF, Yu MY, Cheung JL, Cheng AF,. Evaluation of extraction methods from paraffin wax embedded tissues for PCR amplification of human and viral DNA. J Clin Pathol 2001; 54: 401-3.
20. Insinga RP, Liaw KL, Johnson LG, Madeleine MM,. A systematic review of the prevalence and attribution of human papillomavirus types among cervical, vaginal, and vulvar precancers and cancers in the United States. Cancer Epidemiol Biomarkers Prev 2008; 17: 1611-22.
21. Newcombe RG,. Two-sided confidence intervals for the single proportion: comparison of seven methods. Stat Med 1998; 17: 857-72.
22. Chan PK, Ho WC, Yu MY, Pong WM, Chan AC, Chan AK, Cheung TH, Wong MC, To KF, Ng HK,. Distribution of human papillomavirus types in cervical cancers in Hong Kong: current situation and changes over the last decades. Int J Cancer 2009; 125: 1671-7.
23. Chan PK, Cheung TH, Tam AO, Lo KW, Yim SF, Yu MM, To KF, Wong YF, Cheung JL, Chan DP, Hui M, Ip M,. Biases in human papillomavirus genotype prevalence assessment associated with commonly used consensus primers. Int J Cancer 2006; 118: 243-5.
24. Huang S, Afonina I, Miller BA, Beckmann AM,. Human papillomavirus types 52 and 58 are prevalent in cervical cancers from Chinese women. Int J Cancer 1997; 70: 408-11.
25. Wu EQ, Zhang GN, Yu XH, Ren Y, Fan Y, Wu YG, Kong W, Zha X,. Evaluation of high-risk human papillomaviruses types distribution in cervical cancer in Sichuan province in China. BMC Cancer 2008; 8: 202.
26. Ding DC, Hsu HC, Huang RL, Lai HC, Lin CY, Yu MH, Chu TY,. Type-specific distribution of HPV along the full spectrum of cervical carcinogenesis in Taiwan: an indication of viral oncogenic potential. Eur J Obstet Gynecol Reprod Biol 2008; 140: 245-51.
27. Asato T, Maehama T, Nagai Y, Kanazawa K, Uezato H, Kariya K,. A large case-control study of cervical cancer risk associated with human papillomavirus infection in Japan, by nucleotide sequencing-based genotyping. J Infect Dis 2004; 189: 1829-32.
28. Hwang T,. Detection and typing of human papillomavirus DNA by PCR using consensus primers in various cervical lesions of Korean women. J Korean Med Sci 1999; 14: 593-9.
29. Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S,. Human papillomavirus and cervical cancer. Lancet 2007; 370: 890-907.
30. Wentzensen N, Schiffman M, Dunn T, Zuna RE, Gold MA, Allen RA, Zhang R, Sherman ME, Wacholder S, Walker J, Wang SS,. Multiple human papillomavirus genotype infections in cervical cancer progression in the study to understand cervical cancer early endpoints and determinants. Int J Cancer 2009; 125: 2151-8.
31. de Sanjose S, Quint WG, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B, Tous S, Felix A, Bravo LE, Shin HR, Vallejos CS, de Ruiz PA, et al. Retrospective International Survey and HPV Time Trends Study Group. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 2010; 11: 1048-56.
32. Li N, Franceschi S, Howell-Jones R, Snijders PJ, Clifford GM,. Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: variation by geographical region, histological type and year of publication. Int J Cancer 2011; 128: 927-35.